EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques

Vidyleison N Camargos iD, Shannan L Rossi, Terry L Juelich iD, Jennifer K Smith, Nikos Vasilakis iD, Alexander N Freiberg iD, Rick Nichols iD, Joan Fusco iD

Viruses · 2024

DOI: 10.3390/v16081181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Vidyleison N Camargos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA. Hauptthemen laut MEDLINE: Macaca fascicularis, Marburg Virus Disease, Marburgvirus, Viral Vaccines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Filoviruses, like the Marburg (MARV) and Ebola (EBOV) viruses, have caused outbreaks associated with significant hemorrhagic morbidity and high fatality rates. Vaccines offer one of the best countermeasures for fatal infection, but to date only the EBOV vaccine has received FDA licensure. Given the limited cross protection between the EBOV vaccine and Marburg hemorrhagic fever (MHF), we analyzed the protective efficacy of a similar vaccine, rVSV-MARV, in the lethal cynomolgus macaque model. NHPs vaccinated with a single dose (as little as 1.6 × 107 pfu) of rVSV-MARV seroconverted to MARV G-protein prior to challenge on day 42. Vaccinemia was measured in all vaccinated primates, self-resolved by day 14 post vaccination. Importantly, all vaccinated NHPs survived lethal MARV challenge, and showed no significant alterations in key markers of morbid disease, including clinical signs, and certain hematological and clinical chemistry parameters. Further, apart from one primate (from which tissues were not collected and no causal link was established), no pathology associated with Marburg disease was observed in vaccinated animals. Taken together, rVSV-MARV is a safe and efficacious vaccine against MHF in cynomolgus macaques.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macaca fascicularisMarburg Virus DiseaseMarburgvirusViral VaccinesVesiculovirusAnimalsAntibodies, ViralVaccines, SyntheticDisease Models, AnimalVaccinationMaleFemaleVaccine EfficacyGenetic VectorsImmunogenicity, Vaccine

Stichwörter der Autor:innen

Marburg virusVSVcynomolgus macaqueefficacyfiloviruspseudotyped vectorvaccinevesicular stomatitis virus

Substanzen

Viral VaccinesAntibodies, ViralVaccines, Synthetic

Autor:innen und Institutionen

  • Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA.
  • Departments of Pathology, Microbiology and Immunology, Institute of Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA.
  • Departments of Pathology, Center for Vector-Borne and Zoonotic Diseases, Institute of Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA.
  • Public Health Vaccines, LLC, Cambridge, MA 02142, USA.

ORCID-Profile: Vidyleison N Camargos, Terry L Juelich, Nikos Vasilakis, Alexander N Freiberg, Rick Nichols, Joan Fusco

Förderung

  • Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority
  • Department of Health and Human Services
  • Office of the Assistant Secretary for Preparedness and Response
  • Biomedical Advanced Research and Development Authority

Zitieren

APA

Camargos, V. N., Rossi, S. L., Juelich, T. L., Smith, J. K., Vasilakis, N., Freiberg, A. N., Nichols, R., & Fusco, J. (2024). Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques. Viruses. https://doi.org/10.3390/v16081181

Vancouver

Camargos VN, Rossi SL, Juelich TL, Smith JK, Vasilakis N, Freiberg AN, et al. Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques. Viruses. 2024. doi:10.3390/v16081181

BibTeX
@article{Camargos2024,
  author = {Camargos, Vidyleison N and Rossi, Shannan L and Juelich, Terry L and Smith, Jennifer K and Vasilakis, Nikos and Freiberg, Alexander N and Nichols, Rick and Fusco, Joan},
  title = {Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16081181}
}
Kostenlos starten →